Posts by: admin

News

Bristol-Myers Squibb Company and Celgene Corporation are collaborating on a clinical trial that will evaluate the safety and efficacy of a combined therapy of Bristol-Myers Squibb’s OPDIVO, an investigational PD-1 immune ... Read more

August 20, 2014August 20, 2014

Metastatic Renal Cell Carcinoma Checkpoint Inhibitors Progressing In New Studies

News

According to recent results presented at the American Society of Clinical Oncology (ASCO) clinical trials studying immune checkpoint inhibitors in the treatment of metastatic renal cell carcinoma (mRCC) are quickly ... Read more

August 19, 2014August 19, 2014

Madison Vaccines Incorporated Expands Phase 2 Clinical Trial for Lead DNA Vaccine for Prostate Cancer

News

Madison Vaccines Incorporated, a clinical stage biopharmaceutical company focused on the development of therapeutic vaccine products for patients with prostate cancer, has begun enrolling patients for the expansion of the Phase ... Read more

August 18, 2014

Chemotherapy Effectiveness Could be Aided By Cancer-Eating Bacteria

News

Researchers from the Johns Hopkins Kimmel Cancer Center have found that an attenuated version of Clostridium novyi (C. novyi-NT) bacterium can work as a cancer adjuvant therapy by creating an ... Read more

August 15, 2014August 15, 2014

Immunotherapeutic Targets For Epithelial Ovarian Cancer Identified By Researchers

News

Epithelial ovarian cancer (EOC) is considered the most lethal gynecologic malignancy in women, with a relapse rate of approximately 85% and a 5-year overall survival of 20–30%. The poor clinical ... Read more

August 14, 2014August 14, 2014

Peregrine Pharmaceuticals Reveals Preclinical Data on PS-Targeting Antibodies, Anti-PD-1 Antibodies

News

Peregrine Pharmaceuticals Inc. will announce its preclinical data validating the potent immune-stimulatory mechanism of its phosphatidylserine (PS)-targeting immuno-oncology platform at the 9th Annual Immunotherapies and Vaccine Summit being held August 11-14, 2014 in Boston, ... Read more

August 13, 2014August 13, 2014

Immunotherapy To Be Tested Against Chemotherapy in Non-small Cell Lung Cancer Study

News

A new randomized open-label study will be offered at Houston Methodist Hospital, aiming to compare the therapeutic effects between an emerging immunotherapy drug and an existing chemotherapy drug in the ... Read more

August 12, 2014

Researchers Discover Immune Mechanism Promoting Ovarian Cancer Growth

News

A team of Portuguese researchers has uncovered an important cellular cross-talk promoting ovarian cancer growth. According to the American Cancer Society, there are approximately 21,980 new cases of ovarian cancer ... Read more

August 11, 2014August 11, 2014

Immunosuppressed Microenvironment The Subject of An Emerging Target in Prostate Cancer Management

News

A cutting edge article entitled “Immunosuppressed Microenvironment – An Emerging Target in Prostate Cancer Management” has been published in the peer-reviewed journal Oncology & Hematology Review, explaining how a detailed understanding ... Read more

August 7, 2014August 7, 2014

Syndax Pharmaceuticals’ Entinostat Shown To Improve Treatment Outcomes as Part of Combined Immune Checkpoint Blockade Therapy

News

Syndax Pharmaceuticals Inc., a biopharmaceutical company using epigenetics to treat therapy-resistant cancers, has announced that entinostat, its lead product candidate, in combination with anti-PD1 and anti-CTLA4 monoclonal antibodies, significantly improved treatment ... Read more